93. 原発性胆汁性胆管炎 Primary biliary cholangitis Clinical trials / Disease details


臨床試験数 : 298 薬物数 : 252 - (DrugBank : 59) / 標的遺伝子数 : 35 - 標的パスウェイ数 : 115

  
1 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-004728-36-IT
(EUCTR)
13/03/201205/03/2012A study of Obeticholic Acid versus Placebo in Patients with Primary Biliary Cirrhosis plus long term extension study only with Obeticholic AcidA Phase 3, Double Blind, Placebo Controlled Trial and Long Term Safety Extension of Obeticholic Acid in Patients with Primary Biliary Cirrhosis - A study of OCA in Patients with Primary Biliary Cirrhosis Primary biliary cirrhosis
MedDRA version: 14.1;Level: SOC;Classification code 10019805;Term: Hepatobiliary disorders;System Organ Class: 10019805 - Hepatobiliary disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Acido Obeticolico
Other descriptive name: Obeticholic Acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Acido Obeticolico
Other descriptive name: Obeticholic Acid
Product Name: OCA (INT-747)
Product Code: OCA (INT-747)
INN or Proposed INN: Acido Obeticolico
Other descriptive name: Obeticholic Acid
INTERCEPT PHARMACEUTICALS, INC.NULLNot Recruiting Female: yes
Male: yes
180 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noUnited States;Canada;Poland;Spain;Belgium;Austria;Germany;Netherlands;United Kingdom;Italy;Sweden